

Anti-depressants for depression in Huntington's disease

Submission date	Recruitment status	<input checked="" type="checkbox"/> Prospectively registered
22/09/2025	Recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
02/10/2025	Ongoing	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
25/09/2025	Mental and Behavioural Disorders	<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Huntington's Disease (HD) is a condition that causes problems with movement and thinking, which get worse over time. Many people with HD also experience depression, which affects their quality of life and ability to do everyday activities. Treating depression well could help people with HD and their families feel better and may reduce the need for expensive healthcare. However, depression in HD may be different from depression in people without HD, so it is not clear how well antidepressants work for people with HD. This study aims to find out if a larger trial of antidepressants for depression in HD is possible and what is the best way to measure depression in people with HD.

Who can participate?

Adults who have Huntington's Disease and report mild or moderate symptoms of depression to their doctor may be able to take part.

What does the study involve?

Participants are randomly assigned to receive either a common antidepressant (Sertraline) or a dummy pill (placebo) for 6 months. They have assessments of depression and other HD symptoms at the start of the study and again after 6 months. The study also collects blood and a small sample of the fluid around the brain (using a lumbar puncture) to see if antidepressant treatment changes certain substances linked to inflammation. The study also looks at how many people are willing to join and stay in the study, and which depression measures work best.

What are the possible benefits and risks of participating?

Taking part may help researchers learn more about how to treat depression in HD, which could benefit participants and others in the future. Participants may or may not notice an improvement in their own symptoms. Risks include possible side effects from the medication, and discomfort or risks from blood tests and lumbar puncture. All procedures are explained and carried out by experienced staff.

Where is the study run from?

Cardiff University (UK)

When is the study starting and how long is it expected to run for?
The study is expected to start soon and runs for about 6 months for each participant.

Who is funding the study?
Health and Care Research Wales (UK)

Who is the main contact?
Duncan.Mclauchlan@wales.nhs.uk
DEVISEHD@cardiff.ac.uk

Contact information

Type(s)
Scientific, Principal investigator

Contact name
Dr Duncan McLauchlan

ORCID ID
<https://orcid.org/0000-0002-5356-5019>

Contact details
University Hospital of Wales (UHW)
Heath Park
Cardiff
United Kingdom
CF14 4XW
+44 7791461685
Duncan.Mclauchlan@wales.nhs.uk

Type(s)
Public

Contact name
Dr Paula Foscarini-Craggs

ORCID ID
<https://orcid.org/0000-0001-9511-696X>

Contact details
Centre for Trials Research
School of Medicine
College of Biomedical & Life Sciences
Cardiff University
Cardiff
United Kingdom
CF14 4YS
+44 29 206 87522
DEVISEHD@cardiff.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

1010717

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

02-TC-24-024

Study information

Scientific Title

Developing EVidence for AntidepreSsant ChoicE to Treat Depression in Huntington's Disease

Acronym

DEVISE-HD

Study objectives

The primary objective is to determine the feasibility of a blinded, placebo-controlled trial of antidepressants in people with HD

This feasibility trial has three five secondary objectives:

1. Determine the minimal clinically important difference (MCID), ceiling and floor effects for established measures of depression in HD, to inform outcome selection for a future efficacy trial
2. Determine potential effect sizes in outcome of interest to inform power calculations for a future efficacy trial
3. Determine if there are differences on clinical and fluid biomarkers of disease progression with antidepressant treatment
4. Determine the percentage of participants who are registered in ENROLL
5. Determine the percentage of participants who are registered in HDClarity

Ethics approval required

Ethics approval required

Ethics approval(s)

notYetSubmitted, Ethics committee name not provided (Address not provided, City not provided, Zip/postal code not provided; Telephone number not provided; Email not provided), ref: Reference number not provided

Study design

Double-blind randomized controlled feasibility trial

Primary study design

Interventional

Study type(s)

Treatment, Efficacy

Health condition(s) or problem(s) studied

Antidepressant treatment for depression in individuals with a confirmed genetic diagnosis of Huntington's Disease.

Interventions

Randomisation will take place online through a bespoke system built for the trial to maintain the blind.

Participants will be randomised to receive either 50mg of sertraline or Placebo daily for 6 months. Participants will take the IMP orally. Total follow up duration is 6 months for both arms.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Sertraline

Primary outcome(s)

Feasibility outcomes measured at 6 months post recruitment:

1. Recruitment
2. Retention
3. Data completeness
4. Medication adherence

Key secondary outcome(s)

1. Depression severity is measured using the Montgomery Asberg Depression Rating Scale (MADRS) at baseline, 8 weeks, and 6 months post randomisation
2. Depressive symptoms are measured using the Beck Depression Inventory-II (BDI-II) at baseline, 8 weeks, and 6 months post randomisation
3. Depressive symptoms are measured using the Patient Health Questionnaire-9 (PHQ-9) at baseline, 8 weeks, and 6 months post randomisation
4. Problem behaviours are measured using the Problem Behaviour Assessment at baseline, 8 weeks, and 6 months post randomisation
5. Suicidal ideation and behaviour are measured using the Columbia Suicide Severity Rating Scale (C-SSRS) at baseline, 8 weeks, and 6 months post randomisation
6. Disability is measured using the WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) at baseline, 8 weeks, and 6 months post randomisation
7. Perceived social support is measured using the MOS Social Support Survey at baseline, 8 weeks, and 6 months post randomisation
8. Clinical progression of Huntington's Disease is measured using the critical Unified Huntington's Disease Rating Scale (cUHDRS) at baseline and 6 months
9. Motor function is measured using the motor assessment component of the cUHDRS at baseline and 6 months
10. Functional ability is measured using the functional assessment component of the cUHDRS at baseline and 6 months
11. Cognitive function, including association between visual association and memory/thought

processing and cognitive inhibition, is measured using the cognitive assessment components of the cUHDRS at baseline and 6 months

Completion date

31/05/2027

Eligibility

Key inclusion criteria

1. Adult participants (age ≥ 18), with a confirmed positive genetic test of HD
2. Presenting with a new episode of depression, defined by patient report of low mood and PBAs depressed mood item (i.e. not experiencing depressive symptoms for at least 4 months before the new episode)
3. Presenting with depressive symptomatology defined by patient report of low mood and PBAs depressed mood item score >1 for both severity and frequency

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Key exclusion criteria

1. Currently taking an antidepressant medication or have taken antidepressants in the last six months (for any indication)
2. A previous reaction and/or contraindication to sertraline, and/or Sertraline found to be ineffective
3. Any brain illness/injury, other than HD that, or medication in the opinion of the principal investigator, is likely to contribute to depressive symptoms
4. Any participant with severe depression (PBAs severity >3) or suicidal ideation (due to higher risk of deterioration and suicide in this group).
5. Not able to give informed consent

Date of first enrolment

01/02/2026

Date of final enrolment

31/10/2026

Locations

Countries of recruitment

United Kingdom

England

Wales

Study participating centre

Cardiff and Vale NHS Trust

Cardigan House

University Hospital of Wales

Heath Park

Cardiff

United Kingdom

CF14 4XW

Study participating centre

Birmingham and Solihull Mental Health NHS Foundation Trust

The Uffculme Centre

52 Queensbridge Road

Moseley

Birmingham

United Kingdom

B13 8QY

Study participating centre

Betsi Cadwaladr University Lhb Colwyn Bay Office

Princes Park

Princes Drive

Colwyn Bay

United Kingdom

LL29 8PL

Sponsor information

Organisation

Cardiff University

ROR

Funder(s)

Funder type

Government

Funder Name

Health and Care Research Wales

Alternative Name(s)

Health & Care Research Wales, Health Care Research Wales, Ymchwil lechyd a Gofal Cymru, HCRW

Funding Body Type

Government organisation

Funding Body Subtype

Research institutes and centers

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be available upon request from the trial manager by emailing DEVISEHD@cardiff.ac.uk

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes